Johnson & Johnson topped the list as 2020s most valuable company even though its value decreased by 11% over the past year.
J&J is the new entrant to the list, expanding from 10 companies to 25 this year. Last year’s first-place winner Roche, came second to J&J with a brand value of $7.59 billion. Third place was taken by Bayer, whose value stands at $5.15 billion, despite suffering a dip of 17.1% in valuation.
“By having a strong brand, J&J is more resilient. You do see scandals with big brands, but it takes quite a few before things start to go off the boil,” he said. “I think J&J is still a very well-loved and respected and trusted brand despite some of these issues.”
A large part of the revenue for J&J came as a result is a strong performance in the antimicrobial research and development. Competing with large pharmaceutical players, J&J finished third in the Antimicrobial Resistance Benchmark. It was one of the first companies to announce efforts put into the development of a vaccine candidate against the outbreak of Coronavirus in China. With this break in research, the company’s brand value may increase by next year.
The fastest-depleting company was Pfizer, with a valuation dip of about 20%. With this decrease, the company fell to the sixth position in the list. Some of the deficiencies faced by the company are overly broad product range, low yearly earnings and setbacks in innovation.
Anay Malhotra a qualified computer analyst turned freelancer who writes for Value News where his passion and hard work has earned him a Star Employee for 2 consecutive months. He has been working and exploring varied professionals like Modelling, Event Management and Writing.